Search This Blog
Thursday, November 2, 2017
Saturday, October 21, 2017
CHLORHEXIDINE MOUTH WASH
CHLORHEXIDINE MOUTH WASH
Chlorhexidine gluconate is a germicidal mouthwash that
reduces bacteria in the mouth.
Chlorhexidine gluconate oral rinse is used to treat
gingivitis (swelling, redness, bleeding gums). Chlorhexidine gluconate is
usually prescribed by a dentist.
Chlorhexidine gluconate oral rinse is not for treating all
types of gingivitis. Use the medication only to treat the condition your
dentist prescribed it for. Do not share this medication with another person,
even if they have the same gum symptoms you have.
Chlorhexidine gluconate may also be used for purposes not
listed in this medication guide.
BAD BREATH?
Bad breath can be caused by a decreased flow of saliva.
Saliva plays an important part in digestion and helps to remove odor-causing
particles in the mouth.
Bad breath when you wake up is considered normal. This
happens because the saliva that regularly washes away decaying food and odors
during the day diminishes at night while you sleep. Your mouth becomes dry and
dead cells stick to your tongue and inside of your cheek. Bacteria use these
cells as a food source and expel foul-smelling gases.
How should I use
chlorhexidine gluconate?
Follow all directions on your prescription label. Do not use
this medicine in larger or smaller amounts or for longer than recommended.
Rinse your mouth with chlorhexidine gluconate twice daily
after brushing your teeth.
Measure your dose using the cup provided with the
medication. Swish the medicine in your mouth for at least 30 seconds, then spit
it out. Do not swallow the mouthwash.
Do not add water to the oral rinse. Do not rinse your mouth
with water or other mouthwashes right after using chlorhexidine gluconate.
Chlorhexidine gluconate may leave an unpleasant taste in
your mouth. Do not rinse your mouth to remove this taste after using the
medication. You may rinse the medicine away and reduce its effectiveness.
Use this medication for the full prescribed length of time.
Your symptoms may improve before your gingivitis is completely cleared.
Chlorhexidine gluconate will not treat a viral or fungal infection such as cold
sores, canker sores, or oral thrush (yeast infection).
Visit your dentist at least every 6 months for preventive
tooth and gum care.
Store chlorhexidine gluconate at room temperature away from
moisture and heat.
Usual Adult Dose for
Mucositis:
Usual dose: 15 mL (approximately 0.5 fluid ounces) swished
in the mouth undiluted for 30 seconds and spit out 2 times a day
Comments:
-To decrease medicinal taste, patients should not rinse with
water immediately after use.
-The mouthwash should be used after meals (e.g., after
breakfast and dinner).
Use:
-Use between dental visits to treat gingivitis
(characterized by redness and swelling of the gingivae and gingival bleeding
upon probing)
Usual Adult Dose for
Periodontitis:
Usual dose: 2.5 mg (1 periodontal chip) inserted into a
periodontal pocket with probing pocket depth (PD) of 5 mm or more every 3
months
Maximum dose: Up to 8 periodontal chips/visit
What is the most important
information I should know about chlorhexidine gluconate?
Chlorhexidine gluconate can cause a rare but serious
allergic reaction that may be life-threatening. Get emergency medical help if
you have: hives, severe skin rash; wheezing, difficult breathing; cold sweats,
feeling light-headed; swelling of your face, lips, tongue, or throat.
Do not give this medication to a child or teenager without a
doctor's advice. This medicine may cause severe irritation or chemical burns in
young children.
STRUCTUTE
C22H30Cl2N10
1,6-bis(4-chloro-phenylbiguanido)hexane
Space-filling model of the chlorhexidine molecule, an antiseptic.
Colour code:
Carbon, C: black
Hydrogen, H: white
Nitrogen, N: blue
Chlorine, Cl: green
Sunday, October 15, 2017
DEHYDROEPIANDROSTERONE 25 mg capsules
JAN AUSHADHI KOTTIYAM
Used to treat male Hypogonadizam
Other nuclear receptors
DHEA does not bind to or activate the progesterone, glucocorticoid, or mineralocorticoid receptors.Other nuclear receptor targets of DHEA besides the androgen and estrogen receptors include the PPARα, PXR, and CAR. However, whereas DHEA is a ligand of the PPARα and PXR in rodents, it is not in humans. In addition to direct interactions, DHEA is thought to regulate a handful of other proteins via indirect, genomic mechanisms, including the enzymes CYP2C11 and 11β-HSD1 – the latter of which is essential for the biosynthesis of the glucocorticoids such as cortisol and has been suggested to be involved in the antiglucocorticoid effects of DHEA – and the carrier protein IGFBP1.
DHEA has been found to directly act on several neurotransmitter receptors, including acting as a positive allosteric modulator of the NMDA receptor, as a negative allosteric modulator of the GABAA receptor, and as an agonist of the σ1 receptor.
Neurotrophin receptors
In 2011, the surprising discovery was made that DHEA, as well as DHEA-S, directly bind to and activate the TrkA and p75NTR, receptors of neurotrophins like nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), with high affinity. DHEA was subsequently also found to bind to the TrkB and TrkC with high affinity, though it notably activated the TrkC but not the TrkB. DHEA and DHEA-S bound to these receptors with affinities that were in the low nanomolar range (around 5 nM), although the affinities were nonetheless approximately two orders of magnitude lower relative to highly potent polypeptide neurotrophins like NGF (0.01–0.1 nM). In any case, DHEA and DHEA-S both circulate at requisite concentrations to activate these receptors and were thus identified as important endogenous neurotrophic factors. They have since been labeled "steroidal microneurotrophins", due to their small-molecule and steroidal nature relative to their polypeptide neurotrophin counterparts.Subsequent research has suggested that DHEA and/or DHEA-S may in fact be phylogenetically ancient "ancestral" ligands of the neurotrophin receptors from early on in the evolution of the nervous system. The findings that DHEA binds to and potently activates neurotrophin receptors may explain the positive association between decreased circulating DHEA levels with age and age-related neurodegenerative diseases.
Microtubule-associated protein 2
Similarly to pregnenolone, its synthetic derivative 3β-methoxypregnenolone (MAP-4343), and progesterone, DHEA has been found to bind to microtubule-associated protein 2 (MAP2), specifically the MAP2C subtype (Kd = 27 µM). However, it is unclear whether DHEA increases binding of MAP2 to tubulin like pregnenolone.
Used to treat male Hypogonadizam
Dehydroepiandrosterone (DHEA), also known as androstenolone,
is an endogenous steroid hormone. It is one of the most abundant circulating
steroids in humans, in whom it is produced in the adrenal glands,the gonads,
and the brain, where it functions as a metabolic intermediate in the
biosynthesis of the androgen and estrogen sex steroids. However, DHEA also has a
variety of potential biological effects in its own right, binding to an array
of nuclear and cell surface receptors, and acting as a neurosteroid and
neurotrophin.
FUNCTIONS
As an androgen
DHEA and other adrenal androgens such as androstenedione,
although relatively weak androgens, are responsible for the androgenic effects
of adrenarche, such as early pubic and axillary hair growth, adult-type body
odor, increased oiliness of hair and skin, and mild acne. Women with complete
androgen insensitivity syndrome (CAIS), who have a non-functional androgen
receptor (AR) and are immune to the androgenic effects of DHEA and other
androgens, have absent or only sparse/scanty pubic and axillary hair and body
hair in general, demonstrating the role of DHEA, testosterone, and other
androgens in body hair development at both adrenarche and pubarche.
As a neurosteroid
As a neurosteroid and neurotrophin, DHEA has important effects
in the central nervous system.
BIOLOGICAL ACTIVITY
Hormonal activity
Androgen receptor
Although it functions as an endogenous precursor to more
potent androgens such as testosterone and DHT, DHEA has been found to possess
some degree of androgenic activity in its own right, acting as a low affinity
(Ki = 1 μM), weak partial agonist of the androgen receptor (AR). However, its
intrinsic activity at the receptor is quite weak, and on account of that, due
to competition for binding with full agonists like testosterone, it can actually
behave more like an antagonist depending on circulating testosterone and
dihydrotestosterone (DHT) levels, and hence, like an antiandrogen. However, its
affinity for the receptor is very low, and for that reason, is unlikely to be
of much significance under normal circumstances.
Estrogen receptors
In addition to its affinity for the androgen receptor, DHEA
has also been found to bind to and activate the ERα and ERβ estrogen receptors
with Ki values of 1.1 μM and 0.5 μM, respectively, and EC50 values of >1 μM
and 200 nM, respectively. Though it was found to be a partial agonist of the
ERα with a maximal efficacy of 30–70%, the concentrations required for this
degree of activation make it unlikely that the activity of DHEA at this
receptor is physiologically meaningful. Remarkably however, DHEA acts as a full
agonist of the ERβ with a maximal response similar to or actually slightly
greater than that of estradiol, and its levels in circulation and local tissues
in the human body are high enough to activate the receptor to the same degree
as that seen with circulating estradiol levels at somewhat higher than their
maximal, non-ovulatory concentrations; indeed, when combined with estradiol
with both at levels equivalent to those of their physiological concentrations,
overall activation of the ERβ was doubled. As such, it has been proposed that
DHEA may be an important and potentially major endogenous estrogen in the body.
Other nuclear receptors
DHEA does not bind to or activate the progesterone, glucocorticoid, or mineralocorticoid receptors.Other nuclear receptor targets of DHEA besides the androgen and estrogen receptors include the PPARα, PXR, and CAR. However, whereas DHEA is a ligand of the PPARα and PXR in rodents, it is not in humans. In addition to direct interactions, DHEA is thought to regulate a handful of other proteins via indirect, genomic mechanisms, including the enzymes CYP2C11 and 11β-HSD1 – the latter of which is essential for the biosynthesis of the glucocorticoids such as cortisol and has been suggested to be involved in the antiglucocorticoid effects of DHEA – and the carrier protein IGFBP1.
Neurosteroid activity
Neurotransmitter receptorsDHEA has been found to directly act on several neurotransmitter receptors, including acting as a positive allosteric modulator of the NMDA receptor, as a negative allosteric modulator of the GABAA receptor, and as an agonist of the σ1 receptor.
Neurotrophin receptors
In 2011, the surprising discovery was made that DHEA, as well as DHEA-S, directly bind to and activate the TrkA and p75NTR, receptors of neurotrophins like nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), with high affinity. DHEA was subsequently also found to bind to the TrkB and TrkC with high affinity, though it notably activated the TrkC but not the TrkB. DHEA and DHEA-S bound to these receptors with affinities that were in the low nanomolar range (around 5 nM), although the affinities were nonetheless approximately two orders of magnitude lower relative to highly potent polypeptide neurotrophins like NGF (0.01–0.1 nM). In any case, DHEA and DHEA-S both circulate at requisite concentrations to activate these receptors and were thus identified as important endogenous neurotrophic factors. They have since been labeled "steroidal microneurotrophins", due to their small-molecule and steroidal nature relative to their polypeptide neurotrophin counterparts.Subsequent research has suggested that DHEA and/or DHEA-S may in fact be phylogenetically ancient "ancestral" ligands of the neurotrophin receptors from early on in the evolution of the nervous system. The findings that DHEA binds to and potently activates neurotrophin receptors may explain the positive association between decreased circulating DHEA levels with age and age-related neurodegenerative diseases.
Microtubule-associated protein 2
Similarly to pregnenolone, its synthetic derivative 3β-methoxypregnenolone (MAP-4343), and progesterone, DHEA has been found to bind to microtubule-associated protein 2 (MAP2), specifically the MAP2C subtype (Kd = 27 µM). However, it is unclear whether DHEA increases binding of MAP2 to tubulin like pregnenolone.
Saturday, October 14, 2017
DIACEREIN 50
JAN AUSHADHI KOTTIYAM PRICE - RS - 36.11 / 10 CAP
Diacerein blocks the chemicals that cause inflammation and pain. It builds cartilage (the hard connective tissue in the bones near the joints) in the body.
Diacerein is also known as diacetylrhein, is a slow-acting medicine of the class anthraquinone used to treat joint diseases such as osteoarthritis (swelling and pain in the joints).It works by inhibiting interleukin-1 beta. An updated 2014 Cochrane review found diacerein had a small beneficial effect on pain.Diacerein-containing medications are registered in some European Union and Asian countries and included as a treatment option on several international therapeutic guidelines.
PHARMACOLOGY
Diacerein works by blocking the actions of interleukin-1 beta, a protein involved in the inflammation and destruction of cartilage that play a role in the development of symptoms of degenerative joint diseases such as osteoarthritis. Due to its specific mode of action, which does not involve the inhibition of prostaglandin synthesis, diacerein has been shown to have anti-osteoarthritis and cartilage stimulating properties in vitro and animal models.
DOSAGE AND ADMINISTRATION
The recommended starting dose is 50 mg once daily with evening meal for the first 2 to 4 weeks of treatment, after which the recommended daily dose is 50mg twice daily.The treatment should be taken with food, one with breakfast and the other with evening meal. The capsules must be swallowed intact, without opening them, together with a glass of water.
Special Warning
In 2014 the European Medicines Agency (EMA’s) Pharmacovigilance and Risk Assessment Committee (PRAC) performed a review of diacerein-containing medicines over concerns about its gastrointestinal and liver effects. As a result, the PRAC has introduced additional proposals to manage diacerein’s risks and was satisfied that with new restrictions diacerein’s benefit on pain outweighs the side effects for osteoarthritis treatment.The following recommendations have been made around the use of diacerein:
Due to the potential complications that can occur as a result of diarrhea in older adults, diacerein is no longer recommended in patients aged 65 years and above.
It is also advised that patients start treatment on half the normal dose (i.e. 50 mg daily instead of 100 mg daily), and should stop taking diacerein if diarrhea occurs.
It should not be used in any patient with liver disease or a history of liver disease, and doctors should be monitoring their patients for early signs of liver problems.
The use of diacerein is to be limited to treating symptoms of osteoarthritis affecting the hip or knee.
Diacerein should not be administered during pregnancy and lactation.
The PRAC concluded that the benefit-risk balance of diacerein-containing medicinal products remained favourable in the symptomatic treatment osteoarthritis, subject to the agreed changes to the product information and conditions.
BRAND |
COMPANY |
MRP For 10 S |
|
JAS KOTTIYAM | JAN USHADHI KOTTIYAM | 36.11 | |
DYCERIN 50 | GLENMARK | 101.60 | |
ARTHOCERIN 50 | PULSE | 79.00 | |
ORCERIN 50 | MACLEODS | 87.70 | |
OSTEOGARD 50 | MICRO | 90.00 | |
DURAJOINT 50 | ABOTT | 91.00 |
C19H12O8
Diacetylrhein; Diacerhein;
Saturday, June 3, 2017
Saturday, May 6, 2017
Saturday, April 1, 2017
Anastrozole
Uses
Anastrozole is used in the treatment of breast cancer
How it works
Anastrozole lowers the amount of estrogen (natural female hormone) produced in the body. This can lower or stop the growth of some breast cancer cells that need estrogen to grow.
Common side effects
Headache, Hot flushes, Nausea, Skin rash, Musculoskeletal (bone, muscle or joint) pain, Osteoporosis, Weakness
About
Anastrozole tablets for oral administration contain 1 mg of
anastrozole, a non-steroidal aromatase inhibitor. It is chemically described as
1,3-Benzenediacetonitrile, a, a, a',
a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl). Its molecular formula is
C17H19N5 and its structural formula is:
Anastrozole is an off-white powder with a molecular weight
of 293.4. Anastrozole has moderate aqueous solubility (0.5 mg/mL at 25°C);
solubility is independent of pH in the physiological range. Anastrozole is
freely soluble in methanol, acetone, ethanol, and tetrahydrofuran, and very
soluble in acetonitrile.
Each tablet contains as inactive ingredients: lactose,
magnesium stearate, hydroxypropylmethylcellulose, polyethylene glycol,
povidone, sodium starch glycolate, and titanium dioxide.
SNo | Brand Name | Manufacturers | Type | MRP | ||||
0 | Anastrazole | Jan Aushadhi Kottiyam | Tablet | 114.80/10s | ||||
1 | Altraz | Alkem Laboratories Ltd (Cytomed) | Tablet | 734/14s | ||||
2 | Altraz (1mg) | Alkem (Cytomed) | Tablet | 734/14s | ||||
3 | Altrol | Taj Pharmaceuticals Ltd | Tablet | 722.8/ 14s | ||||
4 | Anabrez | Sun Pharmaceutical Industries Ltd. | Tablet | 246/ 5 tab | ||||
5 | Anastrocare (1 mg) | Medicare Remedies Pvt Ltd | Tablet | 570/ 10s | ||||
6 | Anatero (1 mg) | Lyka Labs Limited | Tablet | 400/ 10s | ||||
7 | Anazol (1mg) | United Biotech | Tablet | 524/10s | ||||
8 | Armilon (1 mg) | Celon Labs | Tablet | 485/10s | ||||
9 | Armotraz | Cipla Limited | Tablet | 495/10s | ||||
10 | Femistra (1 mg) | Cadila Healthcare (Zydus Cadila Healthcare Ltd) | Tablet | 390/10s | ||||
11 | Femitraz (1 mg) | Lupin Laboratories Ltd | Tablet | 462/10s | ||||
12 | PMBC | Miracalus Pharma Pvt Ltd | Tablet | 700/14s | ||||
13 | Qubol (1 mg) | Neon Laboratories Ltd | Tablet | 693/10s | ||||
14 | Redest | Glenmark Pharmaceuticals Ltd. | Tablet | 500/10s | ||||
15 | Redest (1mg) | Glenmark (Onkos) | Film Cotd Tablet | 500/10s | ||||
16 | Stazonex (1 mg) | Abbott Healthcare Pvt Ltd (AHPL) | Tablet | 495/10s | ||||
17 | Xenosoul (1mg) | Xeno | Tablet | 232/ 5s |
Subscribe to:
Posts (Atom)